What's the trade heading into next week's JPMorgan Healthcare Conference?
Every subsector in healthcare attends this conference, explains CNBC Pharmaceuticals Report Mike Huckman and it runs through Thursday so you could see big news being made almost all week.
Ahead of the conference there are a few companies that I recommend you keep a close eye on, he says.
Celgene, which will offer guidance on Monday. The company has been hammered this year on concerns about competition, especially with it blood cancer drug Revlimid. (* Note: The CEO will be on Squawk Box Monday.)
Amgenwill present on Tuesday: Investors will be looking for commentary on anemia drug franchise.
Biogen Idec will offer its first interview since they took themselves off the market. (*Note: The CEO will appear on the Closing Bell on Monday.)
In the pharmaceutical space Pete Najarian likes Celgene and Millennium Pharmaceuticals , Inc.
Got something to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to email@example.com.
Trader disclosure: On Jan 4, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (INTC), (YHOO); Pete Najarian Owns (CSCO), (MSFT); Pete Najarian Owns (AAPL) Options, (NEM) Options, (VLO) Options, (WEN) Options, (YHOO) Options; Jon Najarian Owns (ACI), (AG), (AGU), (BTU), (DE), (DELL), (MON), (MOO), (MOS), (POT), (WEN), (YHOO), (WLP); Jon Najarian Is Short (BSC), (KLAC), (VLO); Charles Schwab Is A Sponsor Of "Fast Money"